Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome
Interventions: ED Sepsis Tracking Sheet; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cerebrospinal Fluid Leak
Interventions: FS VH S/D 500 s-apr, DuraSeal Dural Sealant; Drug · Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more

Conditions: Esophagus Cancer, Esophageal Cancer Stage, Esophageal Cancer, Esophageal Neoplasms, Esophagus Adenocarcinoma, Esophagus, Barrett, Barrett Esophagus, Barrett Adenocarcinoma, Barrett Epithelium, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Barretts Esophagus With High Grade Dysplasia, Barretts Esophagus With Low Grade Dysplasia, Barrett Esophagus, Long-Segment, Barrett's Esophagus With Dysplasia, Unspecified, Barrett's Esophagus With Esophagitis, Gastroesophageal Reflux, Reflux Disease, Esophageal Adenocarcinoma, Esophageal Dysplasia, Esophageal Neoplasms Malignant
Interventions: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 658 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy
Interventions: Bifidobacterium lactis (BB-12), Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 1 Year to 3 Years
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pancreatic Cancers, Pancreatic Diseases
Interventions: Not listed
Lead sponsor: Do Hyun Park; Other
Eligibility: 19 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Cleveland, Ohio

Conditions: Cardiac Arrest
Interventions: Ubiquinol, Ensure; Drug · Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infections, Meningococcal
Interventions: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years to 18 Years
Enrollment: 945 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more

Conditions: Leukemia
Interventions: BAY2402234; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: New York, New York • The Bronx, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Cardiac Toxicity, Lymphoma
Interventions: bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more

Conditions: Fluid Loss, Dialysis
Interventions: CM-1500; Device
Lead sponsor: Zynex Monitoring Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Noise-induced Hearing Loss
Interventions: D-methionine, Placebo; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 351 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Fort Jackson, South Carolina

Conditions: Alzheimer Disease
Interventions: Lovostatin, Ibuprofen; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End Stage Renal Disease, Chronic Kidney Disease
Interventions: SFP, Placebo; Drug · Other
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 28
States / cities: Mobile, Alabama • Northridge, California • Arvada, Colorado + 24 more

Conditions: Autism Spectrum Disorder, Obesity
Interventions: The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Bowel Preparation, Efficacy, Tolerability, Safety, Colon Cancer Screening, Bowel Preparation for Colonoscopy
Interventions: Use of a standardized meal content (food-kit) the day prior to colonoscopy, Polyethylene glycol 3350 - electrolyte solution (GoLYTELY); Other · Drug
Lead sponsor: Joseph Spataro; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Pancreatic Fistula, Distal Pancreatectomy Complications, Falciform Patch Pancreatic Closure, Fibrin Glue Pancreatic Closure
Interventions: Falciform patch and fibrin glue application, standard pancreatic closure; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Cognition, Mental Fatigue, Mood
Interventions: Placebo shot, Functional energy shot; Dietary Supplement
Lead sponsor: The Water Street Collective; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Iselin, New Jersey

Conditions: Growth in Premature Infants
Interventions: liquid protein supplement; Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 26 Weeks to 33 Weeks
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Cholera
Interventions: PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 3,146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more

Conditions: Osteoarthritis, Knee
Interventions: Provant Therapy System; Device
Lead sponsor: Regenesis Biomedical, Inc.; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Lone Tree, Colorado • Spokane, Washington

Conditions: Hydrocephalus
Interventions: Thermal Anisotropy Measurement Device; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Carlumab; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Orange City, Florida • Ann Arbor, Michigan • Charleston, South Carolina

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: Rifampin & midazolam, rifapentine and midazolam; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Immune Deficiency Disorder
Interventions: Octagam 5%, Other marketed IVIG product; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 27
States / cities: Granada Hills, California • Irvine, California • Los Angeles, California + 22 more

Search by objective public record fields.

ED Tracking Sheet Implementation

Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

Study to Investigate the Potential of Probiotics in Yogurt

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Clinical Evaluation of the CM-1500 During Hemodialysis

Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)

The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

Open Trial Obesity CHANGE Program ASD

Assessment of Safety, Quality, and Acceptance of a Bowel Preparation Using a Food Kit With Laxatives

An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas

Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood

Early Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee

Assessment of Flow in Cerebrospinal Fluid Shunts With a Second Generation Wireless Thermal Anisotropy Measurement Device

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

Octagam 5% Versus Comparator Post Marketing Trial